A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Sotigalimab (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Adverse reactions
- 20 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2023 According to Pyxis Oncology, Inc media release, Apexigen has been acquired by Pyxis Oncology
- 15 Oct 2020 Status changed from not yet recruiting to recruiting.